Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 124 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others

EDITORIAL

Empagliflozin: Not just a glorified diuretic

John Mathew

Year : 2016| Volume: 20| Issue : 2 | Page no: 154-156

   This article has been cited by
 
1 Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME
A.J. Scheen,P. Delanaye
Diabetes & Metabolism. 2017;
[Pubmed]  [Google Scholar] [DOI]
2 Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect
Sanjay Kalra,Arpit Jain,Jignesh Ved,AG Unnikrishnan
Indian Journal of Endocrinology and Metabolism. 2016; 20(5): 725
[Pubmed]  [Google Scholar] [DOI]
3 Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics
A.J. Scheen
Diabetes & Metabolism. 2016;
[Pubmed]  [Google Scholar] [DOI]
4 Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME
André J. Scheen
Diabetes Research and Clinical Practice. 2016; 121: 204
[Pubmed]  [Google Scholar] [DOI]

 

Read this article